Drug intelligence / Profile preview

CT-003

Development stage: Unknown
Lead developer: Coagulant Therapeutics
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CT-003 is a 15 kDa llama-derived nanobody therapeutic being developed by Coagulant Therapeutics. It is designed to target both Activated Protein C (APC) and Protease-activated receptor 1 (PAR1) to modulate coagulation and endothelial responses. By binding to the exosite (non-active site) of APC, CT-003 selectively regulates the protein's anticoagulant and cytoprotective activities. This dual-targeting mechanism aims to restore hemostasis and provide endothelial protection in patients suffering from acute conditions such as trauma-induced coagulopathy, hemophilia, and endotheliopathy. The drug is currently in Phase 1 development.

Other names: 15 kDa nanobody

Targets

APC (Activated protein C)F2R (Protease-activated receptor 1)

Beyond the preview

Go deeper on CT-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-003.

Explore the full profile